Chiromics and GlaxoSmithKline Enter into Collaboration
PRINCETON, N.J. -- November 09, 2012
Chiromics LLC today announced a collaboration with GlaxoSmithKline (GSK) to
discover novel classes of small molecules against certain biological targets.
Chiromics’ compound collections are assembled using Chiromics’ core chemical
technology referred to as "cascade catalysis.” This technology was invented in
the MacMillan Laboratories at Princeton University. Cascade catalysis allows
for the creation of “accessible complexity” – a diverse collection of
molecules that is more complex than and differentiated from currently existing
small molecule collections, while retaining drug-like properties, the ability
to develop structure-activity relationships and ease of re-synthesis.
The combination of Chiromics’ chemical compound collection of accessible
complexity, and Chalis^TM, Chiromics’ exclusive hit recognition algorithm for
Affinity Screening, provides an opportunity for identification of new
molecules, that is complementary to conventional high throughput screening
Chiromics’ founder David MacMillan, Ph.D., James S. McDonnell Distinguished
University Professor of Chemistry and Chairman of the Chemistry Department at
Princeton University, stated, “We are pleased to enter into this collaboration
with GSK. This collaboration further validates that our chemical technology
and discovery platform is a potentially valuable gateway to a new set of small
molecules for drug discovery.”
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and
healthcare companies – is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.For further
information please visit www.gsk.com.
About Chiromics LLC
Chiromics LLC is a drug discovery company that designs and synthesizes broadly
diverse chemical compound libraries, using a patented “cascade catalysis”
technology that produces drug-like molecules with a stereochemically defined
framework. The novel structures and accessible complexity of these compounds
expands the access to important disease targets and accelerates the
hit-to-lead time for identification of novel drugs.
Formed in 2009 and based in Princeton, N.J., Chiromics has established
collaborations with leading biotech and pharmaceutical companies for licensing
and screening of its libraries against a broad array of disease targets. For
more information, visit www.chiromics.com.
Colleen Plummer, 267-968-0827
Press spacebar to pause and continue. Press esc to stop.